APA (7th ed.) Citation

Schmitz-Winnenthal, F. H., Hohmann, N., Schmidt, T., Podola, L., Friedrich, T., Lubenau, H., . . . Beckhove, P. (2018). A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. OncoImmunology, 7(4), . https://doi.org/10.1080/2162402X.2017.1303584

Chicago Style (17th ed.) Citation

Schmitz-Winnenthal, Friedrich Hubertus, et al. "A Phase 1 Trial Extension to Assess Immunologic Efficacy and Safety of Prime-boost Vaccination with VXM01, an Oral T Cell Vaccine Against VEGFR2, in Patients with Advanced Pancreatic Cancer." OncoImmunology 7, no. 4 (2018). https://doi.org/10.1080/2162402X.2017.1303584.

MLA (9th ed.) Citation

Schmitz-Winnenthal, Friedrich Hubertus, et al. "A Phase 1 Trial Extension to Assess Immunologic Efficacy and Safety of Prime-boost Vaccination with VXM01, an Oral T Cell Vaccine Against VEGFR2, in Patients with Advanced Pancreatic Cancer." OncoImmunology, vol. 7, no. 4, 2018, https://doi.org/10.1080/2162402X.2017.1303584.